Cantor Fitzgerald Raises PT and Estimates on NewLink Genetics (NLNK); Great Data at ASCO
Tweet Send to a FriendGet Alerts NLNK Hot Sheet
Price: $21.63 --0%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Trade NLNK Now!
Cantor Fitzgerald maintains a 'Buy' on NewLink Genetics (NASDAQ: NLNK) price target of $18.00 (from $15.00).
Analyst, Mara Goldstein, said, "We are raising our 12-month price target to $18 based on our view that the Phase II data generated by HyperAcute Pancreas provides some de-risking to the Phase III trial, prompting us to reduce our five-year discount rate to 45% from 50%."
"We like NewLink for its pipeline of products addressing large and lucrative unmet medical needs and have greater enthusiasm post-ASCO given data presented...We have also updated our estimates to reflect 1Q:12 actual results. Based on a higher share count our new EPS forecast for 2012 is ($1.77) from ($2.98) and our 2013 forecast is now (2.07)."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.41 yesterday, with a 52 week range of $6.25-$13.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Mara Goldstein, said, "We are raising our 12-month price target to $18 based on our view that the Phase II data generated by HyperAcute Pancreas provides some de-risking to the Phase III trial, prompting us to reduce our five-year discount rate to 45% from 50%."
"We like NewLink for its pipeline of products addressing large and lucrative unmet medical needs and have greater enthusiasm post-ASCO given data presented...We have also updated our estimates to reflect 1Q:12 actual results. Based on a higher share count our new EPS forecast for 2012 is ($1.77) from ($2.98) and our 2013 forecast is now (2.07)."
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $12.41 yesterday, with a 52 week range of $6.25-$13.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- AcelRx (ACRX) Target Lifted at Jefferies
- Deutsche Bank Sees Upside in AIG (AIG) Stock
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
